Skip to content

Evaluating Engineered Lactobacillus reuteri with a Zinc Sulfate-Tannic Acid MPN Coating for Acne: A Double-Blind, Randomized Controlled Trial

Evaluating Engineered Lactobacillus reuteri with a Zinc Sulfate-Tannic Acid MPN Coating for Acne: A Double-Blind, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115650
Enrollment
Unknown
Registered
2025-12-29
Start date
2025-12-31
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne

Interventions

Control Group :Apply the Lactobacillus reuteri cream to the acne lesions once daily for 2 weeks.
Experimental Group:Apply the MPN-coated engineered Lactobacillus reuteri cream to the acne lesions once daily for 2 weeks.
Positive Control Group:Apply 0.1% tretinoin cream to the acne lesions once daily for 2 weeks.
Placebo Group:Apply petrolatum-glycerin cream to the acne lesions once daily for 2 weeks.

Sponsors

Shenzhen People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 33 Years

Inclusion criteria

Inclusion criteria: 1.Patients who meet the diagnostic criteria for acne (confirmed by medical history, clinical manifestations and dermoscopy) and are at stages I to III of the Modified International Classification System. 2. Informed consent and voluntary participation of the patient; 3. Sign the informed consent form; 4. Aged between 18 and 33, with general good health condition; 5. The number of inflammatory lesions exceeds 9.

Exclusion criteria

Exclusion criteria: 1.Have used antibiotics within 1 month before the study start. 2.Have used systemic retinoid therapy within 3 months before the study start. 3.Have undergone any other acne treatment within 1 month before the study start. 4.Have any other condition that the investigator considers would make participation unsuitable (e.g., deemed unreliable, non-compliant, or unable to comprehend the study assessments).

Design outcomes

Primary

MeasureTime frame
Percentage change in acne count at Week 8 relative to the baseline.;

Secondary

MeasureTime frame
Percentage change in the number of inflammatory acne lesions at Week 8 relative to the baseline;Percentage change in the number of non-inflammatory acne lesions at Week 8 relative to the baseline; Changes in the relative abundance of Propionibacterium, Lactobacillus, and Staphylococcus in acne-prone skin from baseline to Week 8;

Countries

China

Contacts

Public ContactJianglin Zhang

Shenzhen People’s Hospital (The First Affiliated Hospital, Southern University of Science and

zhang.jianglin@szhospital.com+86 138 7314 3466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026